10 20 30 40 50 60 70 80 1ZV0 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER SIGNALING PROTEIN 01-JUN-05 1ZV0
TITLE MOLECULAR MODEL OF A COMPLEX BETWEEN [SAR1, BPA8]ANGII AND TITLE 2 HAT1 RECEPTOR
CAVEAT 1ZV0 INCORRECT CHIRALITY AT 8 CA CARBONS
COMPND MOL_ID: 1; COMPND 2 MOLECULE: [SAR1, BPA8] ANGIOTENSIN II; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: TYPE-1 ANGIOTENSIN II RECEPTOR; COMPND 7 CHAIN: B; COMPND 8 SYNONYM: AT1; AT1AR
SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 OTHER_DETAILS: MODIFIED RESIDUES : SARCOSINE 1, P- SOURCE 4 BENZOYLPHENYLALANINE (BPA) 8; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 7 ORGANISM_COMMON: HUMAN
KEYWDS VASOCONSTRICTION; ADRENAL ACTIVITY; HYPERTENSION
EXPDTA THEORETICAL MODEL
AUTHOR M.CLEMENT,S.S.MARTIN,M.E.BEAULIEU,C.CHAMBERLAND,P.LAVIGNE, AUTHOR 2 R.LEDUC,G.GUILLEMETTE,E.ESCHER
REVDAT 2 16-AUG-05 1ZV0 1 JRNL REVDAT 1 21-JUN-05 1ZV0 0
JRNL AUTH S.S.MARTIN,M.E.BEAULIEU,C.CHAMBERLAND,P.LAVIGNE, JRNL AUTH 2 R.LEDUC,G.GUILLEMETTE,E.ESCHER JRNL TITL DETERMINING THE ENVIRONMENT OF THE LIGAND BINDING JRNL TITL 2 POCKET OF THE HUMAN ANGIOTENSIN II TYPE I (HAT1) JRNL TITL 3 RECEPTOR USING THE METHIONINE PROXIMITY ASSAY JRNL REF J.BIOL.CHEM. V. 280 27121 2005 JRNL REFN ASTM JBCHA3 US ISSN 0021-9258
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 1ZV0 COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PRAGUE ON 10-JUN-2005. REMARK 100 THE RCSB ID CODE IS RCSB033151.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: THIS MODEL WAS MINIMIZED USING DISTANCE RESTRAINTS REMARK 220 BETWEEN THE LIGAND AND THE RECEPTOR OBTAINED BY THE REMARK 220 METHIONINE PROXIMITY ASSAY. SOFTWARE USED: DISCOVER, REMARK 220 RELEASE 2000, MOLECULAR SIMULATIONS INC., SAN DIEGO
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR B 92 -80.56 75.15 REMARK 500 THR B 141 -104.17 60.02 REMARK 500 ASN B 174 -84.45 72.74 REMARK 500 GLN B 187 148.47 70.24 REMARK 500 ASP B 273 -59.39 78.90 REMARK 500 TYR B 319 122.18 77.68 REMARK 500 ILE B 320 -67.00 105.38 REMARK 500 SER B 346 -80.91 125.31 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASN B 294 ASN B 295 -147.07
DBREF 1ZV0 B 1 359 UNP P30556 AG2R_HUMAN 1 359
SEQRES 1 A 8 ASP ARG VAL TYR ILE HIS PRO PBF SEQRES 1 B 359 MET ILE LEU ASN SER SER THR GLU ASP GLY ILE LYS ARG SEQRES 2 B 359 ILE GLN ASP ASP CYS PRO LYS ALA GLY ARG HIS ASN TYR SEQRES 3 B 359 ILE PHE VAL MET ILE PRO THR LEU TYR SER ILE ILE PHE SEQRES 4 B 359 VAL VAL GLY ILE PHE GLY ASN SER LEU VAL VAL ILE VAL SEQRES 5 B 359 ILE TYR PHE TYR MET LYS LEU LYS THR VAL ALA SER VAL SEQRES 6 B 359 PHE LEU LEU ASN LEU ALA LEU ALA ASP LEU CYS PHE LEU SEQRES 7 B 359 LEU THR LEU PRO LEU TRP ALA VAL TYR THR ALA MET GLU SEQRES 8 B 359 TYR ARG TRP PRO PHE GLY ASN TYR LEU CYS LYS ILE ALA SEQRES 9 B 359 SER ALA SER VAL SER PHE ASN LEU TYR ALA SER VAL PHE SEQRES 10 B 359 LEU LEU THR CYS LEU SER ILE ASP ARG TYR LEU ALA ILE SEQRES 11 B 359 VAL HIS PRO MET LYS SER ARG LEU ARG ARG THR MET LEU SEQRES 12 B 359 VAL ALA LYS VAL THR CYS ILE ILE ILE TRP LEU LEU ALA SEQRES 13 B 359 GLY LEU ALA SER LEU PRO ALA ILE ILE HIS ARG ASN VAL SEQRES 14 B 359 PHE PHE ILE GLU ASN THR ASN ILE THR VAL CYS ALA PHE SEQRES 15 B 359 HIS TYR GLU SER GLN ASN SER THR LEU PRO ILE GLY LEU SEQRES 16 B 359 GLY LEU THR LYS ASN ILE LEU GLY PHE LEU PHE PRO PHE SEQRES 17 B 359 LEU ILE ILE LEU THR SER TYR THR LEU ILE TRP LYS ALA SEQRES 18 B 359 LEU LYS LYS ALA TYR GLU ILE GLN LYS ASN LYS PRO ARG SEQRES 19 B 359 ASN ASP ASP ILE PHE LYS ILE ILE MET ALA ILE VAL LEU SEQRES 20 B 359 PHE PHE PHE PHE SER TRP ILE PRO HIS GLN ILE PHE THR SEQRES 21 B 359 PHE LEU ASP VAL LEU ILE GLN LEU GLY ILE ILE ARG ASP SEQRES 22 B 359 CYS ARG ILE ALA ASP ILE VAL ASP THR ALA MET PRO ILE SEQRES 23 B 359 THR ILE CYS ILE ALA TYR PHE ASN ASN CYS LEU ASN PRO SEQRES 24 B 359 LEU PHE TYR GLY PHE LEU GLY LYS LYS PHE LYS ARG TYR SEQRES 25 B 359 PHE LEU GLN LEU LEU LYS TYR ILE PRO PRO LYS ALA LYS SEQRES 26 B 359 SER HIS SER ASN LEU SER THR LYS MET SER THR LEU SER SEQRES 27 B 359 TYR ARG PRO SER ASP ASN VAL SER SER SER THR LYS LYS SEQRES 28 B 359 PRO ALA PRO CYS PHE GLU VAL GLU
MODRES 1ZV0 PBF A 8 PHE PARA-(BENZOYL)-PHENYLALANINE
HET PBF A 8 33
HETNAM PBF PARA-(BENZOYL)-PHENYLALANINE
FORMUL 1 PBF C16 H15 N O3
HELIX 1 1 HIS B 24 TYR B 56 1 33 HELIX 2 2 THR B 61 TYR B 92 1 32 HELIX 3 3 CYS B 101 HIS B 132 1 32 HELIX 4 4 LEU B 143 LEU B 161 1 19 HELIX 5 5 ILE B 193 GLY B 203 1 11 HELIX 6 6 PHE B 204 ILE B 218 1 15 HELIX 7 7 ASN B 231 ILE B 266 1 36 HELIX 8 8 THR B 282 TYR B 292 1 11 HELIX 9 9 CYS B 296 PHE B 304 1 9 HELIX 10 10 GLY B 306 LEU B 316 1 11
SSBOND 1 CYS B 18 CYS B 274 SSBOND 2 CYS B 101 CYS B 180
CISPEP 1 ASP B 17 CYS B 18 0 -7.14 CISPEP 2 VAL B 179 CYS B 180 0 -9.21 CISPEP 3 ILE B 218 TRP B 219 0 4.92 CISPEP 4 ALA B 277 ASP B 278 0 -11.76 CISPEP 5 PRO B 322 LYS B 323 0 -4.44 CISPEP 6 ALA B 324 LYS B 325 0 9.04 CISPEP 7 SER B 328 ASN B 329 0 -0.73 CISPEP 8 ASN B 329 LEU B 330 0 -4.47 CISPEP 9 SER B 331 THR B 332 0 5.09 CISPEP 10 THR B 332 LYS B 333 0 5.76 CISPEP 11 SER B 335 THR B 336 0 0.94 CISPEP 12 THR B 336 LEU B 337 0 -0.09 CISPEP 13 LEU B 337 SER B 338 0 -6.83 CISPEP 14 TYR B 339 ARG B 340 0 -14.76 CISPEP 15 SER B 342 ASP B 343 0 0.84 CISPEP 16 ASP B 343 ASN B 344 0 2.90 CISPEP 17 ASN B 344 VAL B 345 0 -10.11 CISPEP 18 SER B 346 SER B 347 0 3.86 CISPEP 19 SER B 348 THR B 349 0 0.10 CISPEP 20 THR B 349 LYS B 350 0 1.15 CISPEP 21 PHE B 356 GLU B 357 0 0.45 CISPEP 22 VAL B 358 GLU B 359 0 1.73
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000